Catalent is reducing its workforce by 96 positions at its gene therapy manufacturing facility in Harmans, Maryland, impacting 93 employees at the site and three additional roles in Baltimore. This decision marks a significant shift in the company’s operational strategy amidst ongoing challenges in the biopharmaceutical sector.
The layoffs come as Catalent grapples with increased pressure to streamline operations and enhance efficiency in a competitive market. The gene therapy segment, while promising, has faced hurdles including regulatory scrutiny and fluctuating demand, prompting the company to reassess its workforce needs.
The implications of these layoffs extend beyond immediate job losses, potentially affecting the company’s capacity to meet future production demands and its overall market position. As Catalent navigates this transition, stakeholders in the pharmaceutical supply chain will be closely monitoring the impact on service delivery and product timelines.
Use the database as your supply chain compass →
